Lorcaserin Makes It Past Panel On The Strength Of Effect In Some Patients
The Endocrinologic and Metabolic Drugs Advisory Committee votes 18-4, with one abstention, in favor of lorcaserin for long-term treatment of overweight and obese individuals.
You may also be interested in...
What Belviq Labeling Means For Other Obesity Drug Sponsors
Arena’s Belviq is the first obesity drug approval in over a decade, but it won’t be the only one for long. A look at the FDA-approved labeling for lorcaserin offers a preview of how the agency could handle similar issues for Qnexa and, further down the line, Contrave.
Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators
Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.
Financings Of The Fortnight Parses Federal Funding For Roche/Genentech Alzheimer’s Candidate
Plus news on recent financing activity by Arena, OncoMed, Egalet and Dynavax.